These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26830054)

  • 41. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.
    Ding J; Ma X; Chen Z; Feng K
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):532-3. PubMed ID: 23726651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Development of resistance in bacteria interacting with subinhibitory antibiotic concentrations].
    Cokça F; Altay G
    Mikrobiyol Bul; 1992 Oct; 26(4):333-7. PubMed ID: 1435363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular characterization of amoxicillin-clavulanate resistance in a clinical isolate of Escherichia coli.
    Bellaaj A; Bollet C; Alfeddy N; Limam F; Belhadj C; Regli A; Chollet R; Belhadj O; Ben-Mahrez K
    Microb Drug Resist; 2002; 8(4):267-72. PubMed ID: 12523623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.
    Oteo J; Campos J; Lázaro E; Cuevas O; García-Cobos S; Pérez-Vázquez M; de Abajo FJ;
    Emerg Infect Dis; 2008 Aug; 14(8):1259-62. PubMed ID: 18680650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms.
    Rodríguez-Martínez JM; Ballesta S; Pascual A
    Int J Antimicrob Agents; 2007 Oct; 30(4):366-8. PubMed ID: 17616359
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevalence of resistance to antimicrobials of Escherichia coli isolates from clinical sources at a private hospital in Trinidad.
    Orrett FA; Shurland SM
    Jpn J Infect Dis; 2001 Apr; 54(2):64-8. PubMed ID: 11427743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
    Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in southern Switzerland.
    Borsari AG; Bucher B; Brazzola P; Simonetti GD; Dolina M; Bianchetti MG
    Clin Ther; 2008 Nov; 30(11):2090-5. PubMed ID: 19108796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alarmingly decreasing rates of amoxicillin-clavulanate susceptibility among clinical isolates of Haemophilus influenzae from 2001 to 2009 in a medical center in Taiwan.
    Chung KP; Huang YT; Lee LN; Yu CJ; Lai CC; Hsueh PR
    J Infect; 2011 Feb; 62(2):185-7. PubMed ID: 21145354
    [No Abstract]   [Full Text] [Related]  

  • 52. Amoxicillin/clavulanate (Augmentin) resistant Escherichia coli in bacterial peritonitis after abdominal surgery--clinical outcome in ICU patients.
    Rahnama'i MS; Wagenvoort JH; van der Linden CJ
    Neth J Med; 2009 May; 67(5):173-6. PubMed ID: 19581666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection.
    Robin F; Delmas J; Archambaud M; Schweitzer C; Chanal C; Bonnet R
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2403-8. PubMed ID: 16801418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin.
    Alou L; Cafini F; Sevillano D; Unzueta I; Prieto J
    Int J Antimicrob Agents; 2004 May; 23(5):513-6. PubMed ID: 15120734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and other uropathogens in northern Israel (1995-2005).
    Rock W; Colodner R; Chazan B; Elias M; Raz R
    Isr Med Assoc J; 2007 Nov; 9(11):803-5. PubMed ID: 18085038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antibiotic resistance of bacterial strains in paediatric infections: there are resistance and resistance!].
    Bingen E
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S49-52. PubMed ID: 19000854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.
    Jung R; Messick CR; Pendland SL; Tesoro EP; Losendahl KJ; Schriever CA; Danziger LH
    Antimicrob Agents Chemother; 2000 Mar; 44(3):778-9. PubMed ID: 10681358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
    Koeth LM; Good CE; Saunders KA; Jakielaszek C
    Int J Antimicrob Agents; 2004 Aug; 24(2):144-9. PubMed ID: 15288313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. β-lactamases produced by amoxicillin-clavulanate-resistant enterobacteria isolated in Buenos Aires, Argentina: a new blaTEM gene.
    Di Conza JA; Badaracco A; Ayala J; Rodríguez C; Famiglietti A; Gutkind GO
    Rev Argent Microbiol; 2014; 46(3):210-7. PubMed ID: 25444130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.